LuLIPLEX: A Fast, Highly Sensitive, and Multiplexed Method for the Detection of IgE Against Major Allergens.

Ahead of Print

Publisher: Wiley-Blackwell Country of Publication: Denmark NLM ID: 7804028 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1398-9995 (Electronic) Linking ISSN: 01054538 NLM ISO Abbreviation: Allergy Subsets: MEDLINE

Publication: Copenhagen : Wiley-Blackwell
Original Publication: Copenhagen, Munksgaard.

Background: Diagnosis of allergies is mostly based on the patient's clinical history and allergen provocation tests. Determination of specific IgE (sIgE) profiles can be performed to support allergy diagnosis. This is commonly done in vivo by the skin prick test or in vitro with automated systems. Several platforms exist to quantify sIgE levels, but all these methods require access to specific instruments, often delaying the test's results. The IgE luciferase-linked immunosorbent assay (LuLISA) allows bioluminescent quantification of IgE against peanut in microliter samples, but this method awaits extension to other allergens. This study aimed to validate a new method, named LuLIPLEX, for multiplexed bioluminescent detection of sIgE against 20 major molecular allergens.
Methods: Quantification of sIgE against 12 recombinant or purified food allergens and eight aeroallergens was performed by LuLIPLEX versus standard IgE detection methods (ImmunoCAP, ISAC, ALEX, or NOVEOS). Multiplexed detection of IgE against these 20 allergens was performed within 45 min using 50 μL of serum, plasma, or whole blood samples.
Results: A head-to-head comparison between LuLIPLEX and standard IgE detection methods showed a high correlation among all allergens tested. sIgE profiles in polysensitized subjects could be determined within 45 min in serum and plasma samples, as well as using a single drop of capillary blood.
Conclusions: LuLIPLEX is a rapid and sensitive method to quantify sIgE levels against multiple allergens. Given that the test is very fast and can be performed on small and inexpensive luminometers, the IgE LuLIPLEX could allow point-of-care testing of sIgE profiles in allergic subjects.
(© 2024 The Author(s). Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)

C. A. Akdis, M. Akdis, S. D. Boyd, V. Sampath, S. J. Galli, and K. C. Nadeau, “Allergy: Mechanistic Insights Into New Methods of Prevention and Therapy,” Science Translational Medicine 15, no. 679 (2023): eadd2563.
V. Sampath, E. M. Abrams, B. Adlou, et al., “Food Allergy Across the Globe,” Journal of Allergy and Clinical Immunology 148, no. 6 (2021): 1347–1364.
H. J. Gould and B. J. Sutton, “IgE in Allergy and Asthma Today,” Nature Reviews. Immunology 8, no. 3 (2008): 205–217.
N. C. Thomson and R. Chaudhuri, “Omalizumab: Clinical Use for the Management of Asthma,” Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 6 (2012): 27–40.
M. Maurer, M. Metz, R. Brehler, et al., “Omalizumab Treatment in Patients With Chronic Inducible Urticaria: A Systematic Review of Published Evidence,” Journal of Allergy and Clinical Immunology 141 (2017): 638–649.
N. Charles, I. Kortekaas‐Krohn, E. Kocaturk, et al., “Autoreactive IgE: Pathogenic Role and Therapeutic Target in Autoimmune Diseases,” Allergy 78, no. 12 (2023): 3118–3135.
P. Kolkhir, S. Altrichter, F. M. S. Badloe, et al., “The European Network for IgE‐Mediated Autoimmunity and Autoallergy (ENIGMA) Initiative,” Nature Medicine 30 (2024): 920–922.
P. Gevaert, T. A. Omachi, J. Corren, et al., “Efficacy and Safety of Omalizumab in Nasal Polyposis: 2 Randomized Phase 3 Trials,” Journal of Allergy and Clinical Immunology 146, no. 3 (2020): 595–605.
“FDA Approves First Medication to Help Reduce Allergic Reactions to Multiple Foods After Accidental Exposure,” https://wwwfdagov/news‐events/press‐announcements/fda‐approves‐first‐medication‐help‐reduce‐allergic‐reactions‐multiple‐foods‐after‐accidental.
“Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy.” Registry Name Identifier: NCT04984876, https://www.clinicaltrials.gov/study/NCT04984876?term=NCT04984876&rank=1.
J. Trischler, I. Bottoli, R. Janocha, et al., “Ligelizumab Treatment for Severe Asthma: Learnings From the Clinical Development Programme,” Clinical & Translational Immunology 10, no. 3 (2021): e1255.
L. F. Ensina, J. Bernstein, G. Sussman, et al., “Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria: Results From the Phase‐3 Pivotal Trials,” Journal of Allergy and Clinical Immunology 151 (2023): AB130.
F. D. Finkelman, M. V. Khodoun, and R. Strait, “Human IgE‐Independent Systemic Anaphylaxis,” Journal of Allergy and Clinical Immunology 137, no. 6 (2016): 1674–1680.
P. Bruhns and S. Chollet‐Martin, “Mechanisms of Human Drug‐Induced Anaphylaxis,” Journal of Allergy and Clinical Immunology 147, no. 4 (2021): 1133–1142.
E. M. Abrams, E. S. Chan, and J. Portnoy, “Evolving Interpretation of Screening and Diagnostic Tests in Allergy,” Journal of Allergy and Clinical Immunology: In Practice 9, no. 12 (2021): 4183–4191.
S. B. Sindher, A. Long, A. R. Chin, et al., “Food Allergy, Mechanisms, Diagnosis and Treatment: Innovation Through a Multi‐Targeted Approach,” Allergy 77, no. 10 (2022): 2937–2948.
M. Kulis, B. L. Wright, S. M. Jones, and A. W. Burks, “Diagnosis, Management, and Investigational Therapies for Food Allergies,” Gastroenterology 148, no. 6 (2015): 1132–1142.
E. Calamelli, L. Liotti, I. Beghetti, V. Piccinno, L. Serra, and P. Bottau, “Component‐Resolved Diagnosis in Food Allergies,” Medicina 55, no. 8 (2019): 498.
M. van Hage, C. Hamsten, and R. Valenta, “ImmunoCAP Assays: Pros and Cons in Allergology,” Journal of Allergy and Clinical Immunology 140, no. 4 (2017): 974–977.
E. Potapova, D. Bauersachs, V. Villella, et al., “Validation Study of a New Chemiluminescent Singleplex IgE Assay in a Set of Italian Allergic Rhinitis Patients,” Clinical and Experimental Allergy 51, no. 4 (2021): 604–613.
B. Trouche‐Estival, J. Vitte, A. Martin‐Blondel, et al., “NOVEOS and ImmunoCAP Have Similar Performances for Diagnosing Food Allergies,” Journal of Allergy and Clinical Immunology: In Practice 12 (2024): 1605–1613.
A. B. de Jong, L. D. Dikkeschei, and P. L. Brand, “Sensitization Patterns to Food and Inhalant Allergens in Childhood: A Comparison of Non‐Sensitized, Monosensitized, and Polysensitized Children,” Pediatric Allergy and Immunology 22, no. 2 (2011): 166–171.
M. Migueres, I. Davila, F. Frati, et al., “Types of Sensitization to Aeroallergens: Definitions, Prevalences and Impact on the Diagnosis and Treatment of Allergic Respiratory Disease,” Clinical and Translational Allergy 4 (2014): 16.
B. J. Patchett, B. N. Nriagu, G. Mavraj, et al., “Allergic Polysensitization Clusters: Newly Recognized Severity Marker in Urban Asthmatic Adults,” International Archives of Allergy and Immunology 184, no. 3 (2023): 261–272.
L. Diem, B. Neuherz, J. Rohrhofer, et al., “Real‐Life Evaluation of Molecular Multiplex IgE Test Methods in the Diagnosis of Pollen Associated Food Allergy,” Allergy 77, no. 10 (2022): 3028–3040.
Y. Sereme, N. Casanovas, M. Michel, et al., “IgG Removal Significantly Enhances Detection of Microarray Allergen‐Specific IgE Reactivity in Patients' Serum,” Allergy 76, no. 1 (2021): 395–398.
S. Goyard, B. Balbino, R. S. Chinthrajah, et al., “A Highly Sensitive Bioluminescent Method for Measuring Allergen‐Specific IgE in Microliter Samples,” Allergy 75, no. 11 (2020): 2952–2956.
F. Jabs, M. Plum, N. S. Laursen, et al., “Trapping IgE in a Closed Conformation by Mimicking CD23 Binding Prevents and Disrupts FcepsilonRI Interaction,” Nature Communications 9, no. 1 (2018): 7.
S. Inouye, J. Sato, Y. Sahara‐Miura, S. Yoshida, and T. Hosoya, “Luminescence Enhancement of the Catalytic 19 kDa Protein (KAZ) of Oplophorus Luciferase by Three Amino Acid Substitutions,” Biochemical and Biophysical Research Communications 445, no. 1 (2014): 157–162.
Asthma GIf, “GINA Report, Global Strategy for Asthma Management and Prevention,” https://ginasthmaorg/2023‐gina‐main‐report/ (2023).
M. D. Seidman, R. K. Gurgel, S. Y. Lin, et al., “Clinical Practice Guideline: Allergic Rhinitis,” Otolaryngology and Head and Neck Surgery 152, no. 1 Suppl (2015): S1–S43.
A. F. Santos, C. Riggioni, I. Agache, et al., “EAACI Guidelines on the Diagnosis of IgE‐Mediated Food Allergy,” Allergy 78, no. 12 (2023): 3057–3076.
E. P. Coutant, G. Gagnot, V. Hervin, et al., “Bioluminescence Profiling of NanoKAZ/NanoLuc Luciferase Using a Chemical Library of Coelenterazine Analogues,” Chemistry 26, no. 4 (2020): 948–958.
D. Croote, S. Darmanis, K. C. Nadeau, and S. R. Quake, “High‐Affinity Allergen‐Specific Human Antibodies Cloned From Single IgE B Cell Transcriptomes,” Science 362, no. 6420 (2018): 1306–1309.
D. Croote, J. J. W. Wong, C. Pecalvel, et al., “Widespread Monoclonal IgE Antibody Convergence to an Immunodominant, Proanaphylactic Ara h 2 Epitope in Peanut Allergy,” Journal of Allergy and Clinical Immunology 153, no. 1 (2024): 182–192.
B. Balbino, P. Herviou, O. Godon, et al., “The Anti‐IgE mAb Omalizumab Induces Adverse Reactions by Engaging Fcgamma Receptors,” Journal of Clinical Investigation 130 (2020): 1330–1335.
S. R. Durham and M. H. Shamji, “Allergen Immunotherapy: Past, Present and Future,” Nature Reviews. Immunology 23, no. 5 (2023): 317–328.
S. Barshow, J. Tirumalasetty, V. Sampath, et al., “The Immunobiology and Treatment of Food Allergy,” Annual Review of Immunology 42, no. 1 (2024): 401–425.
P. Gasser, S. S. Tarchevskaya, P. Guntern, et al., “The Mechanistic and Functional Profile of the Therapeutic Anti‐IgE Antibody Ligelizumab Differs From Omalizumab,” Nature Communications 11, no. 1 (2020): 165.
B. Keshavarz, T. A. E. Platts‐Mills, and J. M. Wilson, “The Use of Microarray and Other Multiplex Technologies in the Diagnosis of Allergy,” Annals of Allergy, Asthma & Immunology 127, no. 1 (2021): 10–18.
A. C. M. Platteel, P. van der Pol, J. L. Murk, et al., “A Comprehensive Comparison Between ISAC and ALEX(2) Multiplex Test Systems,” Clinical Chemistry and Laboratory Medicine 60, no. 7 (2022): 1046–1052.
W. W. Busse, W. J. Morgan, P. J. Gergen, et al., “Randomized Trial of Omalizumab (Anti‐IgE) for Asthma in Inner‐City Children,” New England Journal of Medicine 364, no. 11 (2011): 1005–1015.
M. Maurer, A. M. Gimenez‐Arnau, G. Sussman, et al., “Ligelizumab for Chronic Spontaneous Urticaria,” New England Journal of Medicine 381, no. 14 (2019): 1321–1332.
R. A. Wood, A. Togias, S. H. Sicherer, et al., “Omalizumab for the Treatment of Multiple Food Allergies,” New England Journal of Medicine 390 (2024): 889–899.
K. T. Shade, B. Platzer, N. Washburn, et al., “A Single Glycan on IgE Is Indispensable for Initiation of Anaphylaxis,” Journal of Experimental Medicine 212, no. 4 (2015): 457–467.
J. P. Arm, I. Bottoli, A. Skerjanec, et al., “Pharmacokinetics, Pharmacodynamics and Safety of QGE031 (Ligelizumab), a Novel High‐Affinity Anti‐IgE Antibody, in Atopic Subjects,” Clinical and Experimental Allergy 44, no. 11 (2014): 1371–1385.

Institut National de la Santé et de la Recherche Médicale (INSERM); FRM EQU202103012566 the French Medical Research Foundation; ANR-20-CE15-0026 the French National Research Agency; the French Allergology Society (SFA); ERC-2021-CoG 101043749 International ERC_ European Research Council

Keywords: V HH; allergy diagnosis; bioluminescence; immunoglobulin E; luciferase

Date Created: 20241127 Latest Revision: 20241127

20241202

10.1111/all.16403

39601619